Investors keen on regional biotech, but are cautious about deal terms
AFTER raising record amounts of capital in 2021, South-east Asian biotech companies continue to draw in investors this year. However, deal terms are getting tighter, as venture capitalists seek more protection against macroeconomic headwinds.
According to data from private markets specialist Preqin, 2021 was a breakout year for regional biotech, with US$675.9 million worth of venture deals, more than 5 times that of 2020 (see chart).
Fundraising this year remains strong, with 27 biotech venture investments worth US$530.1 million in South-east Asia – mainly Singapore – as of Aug 25. Notable deals include cancer treatment firm Tessa Therapeutics’ US$126 million Series A raise in June, as well as mRNA player RVAC Medicines’ US$140 million Series B round.
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Startups
Vietnam education startup Prep bags US$7 million in Series A funding
Cruise operator Viking prices IPO within range to raise US$1.54 billion: source
Ninja Van axes more than 20 employees in tech team in Singapore
Temasek-backed PsiQuantum to build first commercial quantum computer
Fast-fashion giant Shein wants to sell skincare, toothpaste and toys, too
GoTo narrows Q1 loss to 420 billion rupiah with TikTok deal, cost cuts